Patents by Inventor Pascale Andre

Pascale Andre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20240368281
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: July 15, 2024
    Publication date: November 7, 2024
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 12037392
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: July 16, 2024
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20230303691
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Application
    Filed: June 9, 2023
    Publication date: September 28, 2023
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20230235060
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Application
    Filed: February 6, 2023
    Publication date: July 27, 2023
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 11572410
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: February 7, 2023
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • Treatment of cancers using anti-NKG2A agents
    Patent number: 11225519
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 18, 2022
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann
  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20210238285
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 5, 2021
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20210122821
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 29, 2021
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10870700
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: December 22, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Denis, Carine Paturel, Nicolai Wagtmann
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20200332008
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 22, 2020
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20200299383
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10711063
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 14, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
    Patent number: 10688180
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: June 23, 2020
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 10676523
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: June 9, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
    Patent number: 10494433
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 3, 2019
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Innate Pharma
    Inventors: Pascale Andre, Mathieu Blery, Cecile Bonnafous, Ashok K. Gupta, Luisa M. Salter-Cid, Michael Darron Robbins
  • TREATMENT OF CANCERS USING ANTI-NKG2A AGENTS
    Publication number: 20190322744
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Application
    Filed: June 21, 2019
    Publication date: October 24, 2019
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE SOULAS, NICOLAI WAGTMANN
  • Treatment of cancers using anti-NKG2A agents
    Patent number: 10329348
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: June 25, 2019
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann
  • MONOCLONAL ANTIBODIES AGAINST NKG2A
    Publication number: 20190135938
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
    Type: Application
    Filed: December 20, 2018
    Publication date: May 9, 2019
    Inventors: Alessandro Moretta, Emanuela Marcenaro, Francois Romagne, Pascale Andre
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20190031755
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 31, 2019
    Applicant: INNATE PHARMA
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
  • Monoclonal antibodies against NKG2A
    Patent number: 10160810
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: December 25, 2018
    Assignees: INNATE PHARMA, S.A., UNIVERSITY OF GENOVA
    Inventors: Alessandro Moretta, Emanuela Marcenaro, Francois Romagne, Pascale Andre